SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Shukra Pharmaceuticals touches roof on executing service agreement with APITCO

28 Jul 2025 Evaluate

Shukra Pharmaceuticals is locked its upper circuit at Rs. 19.91, up by 0.39 points or 2.00% from its previous closing of Rs. 19.52 on the BSE.

The scrip opened at Rs. 19.16 and has touched a high and low of Rs. 19.91 and Rs. 19.16 respectively. So far 549899 shares were traded on the counter.

The BSE group 'XT' stock of face value Rs. 1 has touched a 52 week high of Rs. 27.15 on 05-Mar-2025 and a 52 week low of Rs. 5.75 on 21-Nov-2024.

Last one week high and low of the scrip stood at Rs. 21.14 and Rs. 19.16 respectively. The current market cap of the company is Rs. 871.82 crore.

The promoters holding in the company stood at 50.96%, while Institutions and Non-Institutions held 0.11% and 48.93% respectively.

Shukra Pharmaceuticals has executed the service agreement with APITCO. The agreement aims to collaborate on various Healthcare Government assignments across sectors, leveraging APITCO's expertise as a PSU and the company's capabilities in healthcare project management, services, and training. This collaboration aims to contribute meaningfully to national-level developmental, industrial, and consulting initiatives.

The company will operate as a business associate / healthcare project management consultant / service & training provider for various healthcare government assignments. All projects undertaken through this collaboration will be executed under defined service level agreements (SLAs) with detailed scope, timelines, deliverables, and performance standards.

Shukra Pharmaceuticals is an ambitious organisation with a deep-rooted focus on sustainability with its impressive range of solutions.

Shukra Pharma Share Price

31.87 -1.67 (-4.98%)
11-May-2026 13:49 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1872.20
Dr. Reddys Lab 1295.00
Cipla 1322.70
Zydus Lifesciences 948.00
Lupin 2278.00
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×